MaxCyte, Inc. reports news on its cell-engineering technology business for biotechnology and pharmaceutical customers developing next-generation cell therapeutics. Company updates center on Flow Electroporation technology, ExPERT instruments, SeQure gene editing assessment services, and Strategic Platform License relationships that can generate product, license, research, clinical and program-related revenue.
Recurring developments include quarterly and annual financial results, revenue guidance, installed instrument activity, licensed customer programs, product launches such as ExPERT DTx for high-throughput electroporation, and corporate governance matters including executive appointments and equity compensation grants.
MaxCyte (NASDAQ: MXCT) reported Q4 2025 revenue $7.3M and FY2025 revenue $33.0M, down 16% and 15% year-over-year respectively. Gross margin for FY2025 was 81%. Cash, cash equivalents and investments were $155.6M at year-end; company expects at least $136M at end of 2026. 2026 revenue guidance: $30–32M (Core $25–27M; SPL ~ $5M).
The company cited a 15% reduction in purchases from its largest SPL customer impacting 2025 and expects stabilization and later growth in H2 2026.
MaxCyte (Nasdaq: MXCT) appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, whose transition was previously announced in November 2025. Mr. Ahuja brings over 20 years of finance leadership at Agilent, including investor relations and FP&A roles.
The company said he will strengthen financial operations, support disciplined execution, and help advance strategic priorities for its electroporation platform in cell and gene therapy.
MaxCyte (NASDAQ: MXCT) launched ExPERT DTx™, a 96-well high-throughput electroporation platform for research and drug discovery on Feb 24, 2026. The modular system processes up to 96 samples in a single three-minute run with the R-50x96™ assembly and 12 detachable 8-well strips.
The platform emphasizes low cellular stress, consistent well-to-well performance, validated applications from cell and gene therapy to protein production, and software enabling remote experiment design and easy transfer to other ExPERT instruments for scale-up into cGMP workflows.
MaxCyte (NASDAQ: MXCT) will release fourth quarter and full year 2025 financial results after U.S. market close on March 24, 2026. Management will host a conference call at 4:30 p.m. ET the same day to discuss results.
Investors must register online to join the call; a live and archived webcast will be available in the company’s Events section at the investor website.
MaxCyte (Nasdaq: MXCT) provided preliminary unaudited results for the quarter and year ended December 31, 2025. Q4 core revenue is expected to be $6.6M–$6.7M and FY2025 core revenue is expected to be $29.5M–$29.6M. SPL program revenue is expected to be $0.4M–$0.6M for Q4 and $3.3M–$3.5M for FY2025. Cash, cash equivalents, and investments are expected to be approximately $155.6M as of December 31, 2025. Management described 2025 as challenging but said core revenue was in line with guidance, noted cost-structure improvements and program rationalization, and stated an expectation to return to revenue growth in H2 2026. Final audited results are expected in March 2026.
Cellares announced Ali Soleymannezhad as Chief Commercial Officer to lead global commercial expansion and prepare the company for a future IPO.
The appointment follows five global manufacturing agreements with partners including Bristol Myers Squibb and Kite, the FDA’s first Advanced Manufacturing Technology (AMT) designation for the Cell Shuttle platform, and plans to support multiple clinical trials in 2026. Soleymannezhad brings over two decades of commercialization experience from MaxCyte (NASDAQ: MXCT) and Tosoh Bioscience and will oversee enterprise sales, business development, and licensing for Cellares’ IDMO Smart Factories across the US, Europe, and Japan.
MaxCyte (Nasdaq: MXCT) announced that Chief Financial Officer Douglas Swirsky will transition from his CFO role in the first half of 2026. Mr. Swirsky will remain CFO until a successor is appointed, will support a structured successor search, and will continue in an advisory capacity after the transition to support strategic initiatives and continuity.
The company and Mr. Swirsky say the planned, orderly handoff is not expected to affect operations, results, financial reporting cadence, or strategic priorities.
MaxCyte (NASDAQ: MXCT) reported third quarter 2025 results and reiterated full-year 2025 guidance on Nov 12, 2025. Total revenue was $6.8M in Q3 2025, down 16% year-over-year; core revenue was $6.4M, down 21% YoY. Gross profit was $5.2M (77% gross margin); non-GAAP adjusted gross margin was 81% versus 85% in Q3 2024. Q3 net loss was $12.4M; adjusted EBITDA loss improved to $10.0M from $13.0M. Installed instrument base rose to 830. Management reiterated 2025 guidance: core revenue flat to -10% and ~$5M SPL program revenue; expected year-end cash of $152M–$155M.
MaxCyte (NASDAQ: MXCT) reported preliminary third-quarter 2025 results and reiterated full-year 2025 revenue guidance on Nov 5, 2025. Q3 total revenue was $6.8M with core revenue $6.4M and SPL program-related revenue $0.4M. Gross margin was $5.2M (77%), with a non-GAAP adjusted gross margin of 81% excluding SPL and inventory reserves. Cash, cash equivalents and investments totaled $158.0M at September 30, 2025. The company is delaying the formal Q3 release and call to complete impairment testing of goodwill and long-lived assets; guidance sees year-end cash of $152M–$155M and SPL revenue ~$5M for 2025.
MaxCyte (NASDAQ: MXCT) will report third quarter 2025 financial results after the U.S. market close on Wednesday, November 5, 2025.
Company management will host an earnings conference call at 4:30 p.m. Eastern Time the same day. Investors must register online in advance to join the call, and a live and archived webcast will be available in the Events section of MaxCyte's investor website at https://investors.maxcyte.com/.